Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) received a consensus rating of “Hold” from the thirteen rating agencies that currently cover the company, Marketbeat reports. One financial analyst has assigned the stock a sell rating, five have issued a hold rating and three have assigned the company a buy rating. The 1-year average price target among analysts who updated their stock coverage in the last year is $52.51.
Several research analysts recently commented on the title. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 report. JPMorgan Chase & Co. raised its price target on shares of Fresenius Medical Care AG & Co. KGaA from €48.70 ($49.19) to €51.00 ($51.52) and assigned the company an “underweight” rating in a Thursday, May 5 research note. . Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and raised its price target for the company from $30.30 to 33.70 $ in a research note from Monday, June 27. Finally, Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a research note Wednesday, June 22.
Institutional investors weigh in on Fresenius Medical Care AG & Co. KGaA
Hedge funds and other institutional investors have recently changed their stock holdings. Ellevest Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 96.6% in the 4th quarter. Ellevest Inc. now owns 1,148 shares of the company worth $37,000 after purchasing an additional 564 shares in the last quarter. Tcwp LLC purchased a new equity stake in Fresenius Medical Care AG & Co. KGaA in Q1 valued at approximately $44,000. SRS Capital Advisors Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 36.0% in Q1. SRS Capital Advisors Inc. now owns 1,545 shares of the company worth $52,000 after buying 409 additional shares in the last quarter. Creative Financial Designs Inc. ADV acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q1 for approximately $67,000. Finally, GHP Investment Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q1 worth approximately $72,000. 4.73% of the shares are currently held by institutional investors.
Pricing performance of Fresenius Medical Care AG & Co. KGaA
NYSE FMS shares opened at $22.78 on Friday. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $22.09 and a 52-week high of $41.38. The stock has a market capitalization of $13.35 billion, a price/earnings ratio of 13.02, a PEG ratio of 0.90 and a beta of 1.21. The company’s 50-day moving average price is $26.39 and its 200-day moving average price is $30.52. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly results on Wednesday, May 4. The company reported earnings per share (EPS) of $0.38 for the quarter, beating the consensus estimate of $0.30 by $0.08. The company posted revenue of $5.10 billion for the quarter, versus $4.97 billion expected by analysts. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 4.91% and a return on equity of 6.99%. As a group, research analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 1.98 for the current fiscal year.
Fresenius Medical Care AG & Co. KGaA reduces its dividend
The company also recently disclosed an annual dividend, which was paid on Friday, May 27. Investors of record on Monday, May 16 received a dividend of $0.7093 per share. This represents a dividend yield of 3.4%. The ex-dividend date was Friday, May 13. The dividend distribution rate of Fresenius Medical Care AG & Co. KGaA is currently 28.00%.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here